eHealth in Treatment of Gestational Diabetes (eMOMGDM)
Key facts
- Who runs it
- Helsinki University Central Hospital
- Where
- Finland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 200 people, planned
- Started
- 10 Mar 2021
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- eMOM GDM application
- Record updated
- 24 September 2026
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- GDM diagnoses at 24-28 gestational weeks
Who cannot take part
- type 1 or type 2 diabetes
- severe psychiatric disorder (that complicates participation to the study)
- use of medication that influences glucose metabolism (such as continuous therapy with oral corticosteroids or metformin)
- multiple pregnancy
- physical disability
- current substance abuse
- significant difficulty in cooperating (e.g. inadequate Finnish language skills)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The overall aim of the eMOM GDM-project is to develop and evaluate a novel system to clinical decision making and patient behavior change in treatment of GDM, combining diet, physical activity, sleep, heart rate (e.g. stress), and glucose monitoring within a single system (the eMOM GDM application), and linking the developed application tool for the normal health care system in a new way.
Read full original descriptionShow less
In this second phase of the project, the effect of eMOM GDM application on maternal and neonatal outcomes will be evaluated in a randomized controlled study design. The follow-up study continues until 3 months postpartum.
The 2 groups in the trial
- Intervention (eMOM GDM application)Treatment being tested
Participants in the intervention group will use the eMOM GDM -application one week/month. The participants will also receive regular antenatal care in maternity clinics and hospitals. In addition they will meet a study nurse three times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum).
Treatment: eMOM GDM application
- ControlNo study treatment, for comparison
Participants in the control group will meet a study nurse 3 times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum). They also receive regular antenatal care in maternity clinics and hospitals.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- eHealth in Treatment of Gestational Diabetes - eMOM GDM -Study (Phase 2)
- Record updated
- 24 September 2026